

Enterprise Pharmacy and Therapeutics Committee Meeting
Call in number 646-876-9923 Meeting ID 943 2189 7812
January 30th, 2023
6:00PM-8:00PM EST

Pre-register at jplante@amerihealthcaritas.com prior to the meeting

<u>Subject</u>	<u>Presenter</u>
1. Call to Order	B. Himelstein
2. Conflict of Interest Disclosures	S. Cherian
3. Enterprise P&T Charter	S. Cherian
4. BCC Positive Changes, PA Criteria Updates	C. Meny
5. Review and approval of October P&T and November Proxy Minutes	S. Cherian
6. Old Business	PerformRx
A. Self-administered Disease Modifying Therapies (DMTs) for Multiple Sclerosis (MS).....p. 113	
B. Healthcare professional (HCP) administered Disease Modifying Therapies (DMTs) for Multiple Sclerosis (MS).....p. 117	
C. ACLA – Fabrazyme.....p. 120	
D. White Blood Cell Stimulators.....p. 122	
E. ACNH – Hepatitis Cp. 127	
F. ACOH Medications without Specific Criteriap. 131	
G. BCC – Adakveo.....p. 132	
H. BCC – Siklos.....p. 133	
I. BCC – Retinoic Acid.....p. 134	
J. ACDE – 1/1/2023 PDL Change PA Criteria Updatesp. 136	
K. ACDE - Janus Kinase Inhibitors for Nonsegmental Vitiligop. 163	
7. New Business	PerformRx
A. Preferred Antidiabetic Agents.....p. 165	
B. Long-Acting Injectable Antipsychoticsp. 167	
C. Continuous Glucose Monitorsp. 169	
D. ACNH – Buprenorphinep. 177	
E. Gonadotropin Releasing Hormone Antagonistsp. 179	
F. Injectable/Infusible Bone-Modifying Agents for Osteoporosis and Paget’s Diseasep. 189	
G. Pulmonary Biologics for Asthma and Eosinophilic Conditions.....p. 201	
H. SMN2 Splicing Modifiers for the Treatment of Spinal Muscular Atrophy (SMA).....p. 216	

I. Oxlumo.....	p. 222
J. SHSC – Short Acting Opioids.....	p. 224
K. ACFL – Step Therapy Exception.....	p. 227
L. ACFL – Prior Authorization Exception.....	p. 228
M. Oxbryta.....	p. 229
N. EviCore	p. 233
8. Drug Reviews:	PerformRx
A. Therapeutic Class:	
1. Direct Oral Anticoagulants.....	p. 313
2. Calcium Channel Blockers	p. 318
3. Pulmonary Arterial Hypertension with PA Criteria	p. 331
4. Second Generation Antihistamines with PA Criteria.....	p. 345
5. Inhaled Anticholinergics.....	p. 356
B. Single Products:	PerformRx
1. Xenpozyme with PA Criteria.....	p. 367
2. Spevigo with PA Criteria.....	p. 378
3. Sotyktu with PA Criteria	p. 387
4. Methergine	p. 404
5. Hemgenix with PA Criteria.....	p. 410
6. Tzield with PA Criteria	p. 420
9. New Products	PerformRx
9. Prior Authorization Criteria Review:	PerformRx
A. Prior Authorization Criteria Annual Review:	
1. Agents to Treat Constipation	p. 439
2. Amifampridine	p. 443
3. Botulinum Toxins A&B.....	p. 445
4. Dojolvi.....	p. 451
5. Glycopyrrolate	p. 452
6. ACNH – Onychomycosis	p. 453
7. Hemophilia Factor VIII Replacement Products for Hemophilia A.....	p. 459
8. Hemlibra	p. 463
9. Juxtapid	p. 465
10. Natpara.....	p. 471
11. Proton Pump Inhibitors	p. 473
12. Transthyretin-mediated Amyloidosis Agents	p. 477
13. SHSC – Opioid Dependence Agents.....	p. 483
14. Medications for Use in ADHD Treatment for Members 21 and Older.....	p. 485
15. ACDE – Retinoic Acid Derivatives for Acne Treatment	p. 487

B. Prior Authorization Criteria Annual Review without Clinical Changes	
1. Adrenal Enzyme Inhibitors for Cushing's Disease (Isturisa)	p. 490
2. Alpha-1 Proteinase Inhibitors (Human).....	p. 492
3. Anti-Parkinson's Agents for OFF Episodes.....	p. 500
4. Benlysta.....	p. 504
5. Blincyto.....	p. 506
6. Carisoprodol	p. 510
7. Corlanor.....	p. 512
8. Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Modulators.....	p. 513
9. Doxylamine/Pyridoxine	p. 516
10. Emergency Use Authorization (EUA) Drugs/Products for COVID-19.....	p. 519
11. Emflaza	p. 522
12. AHDC - Opioid Containing Products.....	p. 524
13. Growth Hormone (GH) for Growth Failure or GH Deficiency	p. 527
14. Hyaluronic Derivatives.....	p. 535
15. Ileal bile acid transporter inhibitor (IBAT) [Bylvay]	p. 538
16. Levalbuterol HFA Inhaler.....	p. 540
17. SHSC - Long Acting (LA) Opioid Containing Products	p. 542
18. Mucopolysaccharidosis IV (Maroteaux-Lamy Syndrome) Agents - Naglazyme	p. 545
19. Ocalvia	p. 546
20. Adrenergic, alpha-receptor-blocking agent (Phenoxybenzamine).....	p. 548
21. Reblozyl.....	p. 549
22. Tavneos.....	p. 551
23. BCC Injectable Prostacyclin Pulmonary Antihypertensives	p. 553
24. KF/AHC/CHC – Compound Products	p. 555
25. ACNH – Rho Kinase Inhibitors	p. 556
26. BCC – Lemtrada.....	p. 560
C. New Prior Authorization Criteria	
1. Skysona.....	p. 562
2. Relyvrio	p. 563
3. BCC – Vtama	p. 564
4. BCC – Zoryve.....	p. 565

10. Recalls

PerformRx

11. Adjourn

B. Himmelstein

*****NEXT MEETING: April 24th, 2023*****